Predictions
Precision BioSciences Inc
Start price
Target price
Perf. (%)
€0.86
15.03.23
15.03.23
€16.09
15.03.24
15.03.24
-59.36%
16.03.24
16.03.24
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€36.37
13.03.23
13.03.23
-
13.03.24
13.03.24
-27.88%
14.03.24
14.03.24
Novo Nordisk A/S ADR
Start price
Target price
Perf. (%)
€131.50
13.03.23
13.03.23
-
13.04.23
13.04.23
15.59%
14.04.23
14.04.23
Could be very worthwhile Investment >20% year
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€302.40
13.03.23
13.03.23
-
13.04.23
13.04.23
11.97%
14.04.23
14.04.23
Could be very worthwhile Investment >20% year
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€307.70
13.03.23
13.03.23
€350.10
13.03.24
13.03.24
124.73%
14.03.24
14.03.24
Sage Therapeutics Inc.
Start price
Target price
Perf. (%)
€42.33
13.03.23
13.03.23
€56.02
13.03.24
13.03.24
-56.77%
14.03.24
14.03.24
Concert Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€7.88
12.03.23
12.03.23
-
12.03.24
12.03.24
0.00%
13.03.24
13.03.24
Lexicon Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€2.15
11.03.23
11.03.23
-
11.03.24
11.03.24
18.11%
12.03.24
12.03.24
Galmed Pharmaceuticals Ltd.
Start price
Target price
Perf. (%)
€0.42
11.03.23
11.03.23
-
11.03.24
11.03.24
-21.70%
12.03.24
12.03.24
Amicus Therapeutics Inc.
Start price
Target price
Perf. (%)
€10.70
11.03.23
11.03.23
-
11.03.24
11.03.24
2.80%
12.03.24
12.03.24
Invitae Corp
Start price
Target price
Perf. (%)
€1.30
11.03.23
11.03.23
€0.40
11.03.24
11.03.24
-93.65%
12.03.24
12.03.24
Could be worthwhile Investment >10% per year
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Promis Neurosciences Inc.
Start price
Target price
Perf. (%)
€4.22
11.03.23
11.03.23
€4.60
11.03.24
11.03.24
18.48%
19.05.23
19.05.23
ROE lower than 10% per year
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Canopy Growth Corp
Start price
Target price
Perf. (%)
€1.93
11.03.23
11.03.23
€0.30
11.03.24
11.03.24
-77.19%
08.07.23
08.07.23
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Risky balance sheet
Agios Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€20.20
10.03.23
10.03.23
-
10.03.24
10.03.24
38.61%
11.03.24
11.03.24